Sumitomo files iPS cell therapy for Parkinson’s approval in Japan
Japanese drugmaker Sumitomo Pharma Company (TYO: 4506) and Tokyo-based Racthera announced that on August 5, they had submitted an application of manufacturing and marketing authorization for allogeneic iPS cell-derived dopaminergic neural progenitor cells (generic name: raguneprocel) indication of the improvement of motor functions during the off-time period of patients with advanced Parkinson’s disease.
Sumitomo Pharma is actively involved in developing treatments for Parkinson's disease, including another iPS cell-derived cell therapy and a drug called Trerief (zonisamide). This drug was approved in Japan for the treatment for parkinsonism in dementia with Lewy bodies (DLB) in 2028. The drug is also marketed as an antiepileptic, branded Zonegran, by Eisai (TYO: 4523).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze